Abstract
The compound 1 - chloro - 2,4 - dinitrobenzene (DNCB) is a potent contact allergen that has been used in the past decade by many dermatologists for the treatment of benign skin disorders, such as recalcitrant viral warts<sup>1</sup>and extensive alopecia areata.<sup>2</sup>In this issue of theArchives, however, the investigations of Black et al<sup>3</sup>cast serious doubts on the use of DNCB. This editorial provides further arguments against the use of this compound. Five years ago, two groups of independent investigators found that DNCB acts as a mutagen in the bacterial plate incorporation assay (Ames test).<sup>4,5</sup>Both groups used various strains of<i>Salmonella typhimurium</i>as indicator organisms, and both groups obtained positive results with and without metabolic activation by rat liver S-9 fraction, a homogenate containing hepatocellular microsomes. Moreover, Summer and Göggelmann<sup>5</sup>showed that DNCB depletes the activity of glutathione S-transferase in rat skin,
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
